{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:43:31Z","timestamp":1781534611839,"version":"3.54.5"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T00:00:00Z","timestamp":1769299200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Med"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s00109-026-02645-1","type":"journal-article","created":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T03:01:21Z","timestamp":1769310081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Alcohol induces sorafenib resistance in hepatocellular carcinoma: A translational study"],"prefix":"10.1007","volume":"104","author":[{"given":"Ano\u00efsia","family":"Courtois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Mari\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Fouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momar","family":"Diouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Esparteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rard","family":"Ducournau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Marticho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Naassila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Nguyen-Khac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4031-224X","authenticated-orcid":false,"given":"Ingrid","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,25]]},"reference":[{"issue":"2","key":"2645_CR1","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.jhep.2018.10.008","volume":"70","author":"N Ganne-Carri\u00e9","year":"2019","unstructured":"Ganne-Carri\u00e9 N, Nahon P (2019) Hepatocellular carcinoma in the setting of alcohol-related liver disease. J Hepatol 70(2):284\u2013293","journal-title":"J Hepatol"},{"issue":"47","key":"2645_CR2","doi-asserted-by":"publisher","first-page":"17756","DOI":"10.3748\/wjg.v20.i47.17756","volume":"20","author":"E Ceni","year":"2014","unstructured":"Ceni E, Mello T, Galli A (2014) Pathogenesis of alcoholic liver disease: role of oxidative metabolism. World J Gastroenterol 20(47):17756\u201317772","journal-title":"World J Gastroenterol"},{"key":"2645_CR3","unstructured":"Ferlay J, Ervik M, Lam F et al (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. https:\/\/gco.iarc.who.int\/today\/. Accessed 11 Sept 2024"},{"issue":"9","key":"2645_CR4","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1002\/cncr.31215","volume":"124","author":"CE Costentin","year":"2018","unstructured":"Costentin CE, Mourad A, Lahmek P et al (2018) Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective, nationwide study: Delayed Diagnosis of Alcohol-Related HCC. Cancer 124(9):1964\u20131972","journal-title":"Cancer"},{"key":"2645_CR5","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1200\/EDBK_200939","volume":"38","author":"LY Mak","year":"2018","unstructured":"Mak LY, Cruz-Ram\u00f3n V, Chinchilla-L\u00f3pez P et al (2018) Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book 38:262\u2013279","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"10360","key":"2645_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A (2022) Hepatocellular carcinoma. Lancet 400(10360):1345\u20131362","journal-title":"Lancet"},{"issue":"4","key":"2645_CR7","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359(4):378\u2013390","journal-title":"N Engl J Med"},{"issue":"19","key":"2645_CR8","doi-asserted-by":"publisher","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","volume":"64","author":"SM Wilhelm","year":"2004","unstructured":"Wilhelm SM, Carter C, Tang L et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64(19):7099\u20137109","journal-title":"Cancer Res"},{"issue":"10","key":"2645_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR (2019) A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol 16(10):589\u2013604","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"2645_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M et al (2022) Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 19(3):151\u2013172","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"2645_CR11","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J et al (2022) BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol 76(3):681\u2013693","journal-title":"J Hepatol"},{"issue":"1","key":"2645_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0187-x","volume":"5","author":"W Tang","year":"2020","unstructured":"Tang W, Chen Z, Zhang W et al (2020) The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduct Target Ther 5(1):87","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2645_CR13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.bbcan.2017.10.002","volume":"1868","author":"L Niu","year":"2017","unstructured":"Niu L, Liu L, Yang S, Ren J, Lai PBS, Chen GG (2017) New insights into sorafenib resistance in hepatocellular carcinoma: responsible mechanisms and promising strategies. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1868(2):564\u2013570","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"3","key":"2645_CR14","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00204-019-02395-9","volume":"93","author":"S Di Giacomo","year":"2019","unstructured":"Di Giacomo S, Briz O, Monte MJ et al (2019) Chemosensitization of hepatocellular carcinoma cells to sorafenib by \u03b2-caryophyllene oxide-induced inhibition of ABC export pumps. Arch Toxicol 93(3):623\u2013634","journal-title":"Arch Toxicol"},{"issue":"1","key":"2645_CR15","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/hep.30989","volume":"72","author":"CON Leung","year":"2020","unstructured":"Leung CON, Tong M, Chung KPS et al (2020) Overriding adaptive resistance to sorafenib through combination therapy with Src homology 2 domain-containing phosphatase 2 blockade in hepatocellular carcinoma. Hepatology 72(1):155\u2013168","journal-title":"Hepatology"},{"issue":"7","key":"2645_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04387-y","volume":"79","author":"C Mari\u00e9","year":"2022","unstructured":"Mari\u00e9 C, Fouquet G, Courtois A et al (2022) Mechanisms of chronic alcohol exposure-induced aggressiveness in cellular model of HCC and recovery after alcohol withdrawal. Cell Mol Life Sci 79(7):366","journal-title":"Cell Mol Life Sci"},{"issue":"7854","key":"2645_CR17","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","volume":"592","author":"D Pfister","year":"2021","unstructured":"Pfister D, N\u00fa\u00f1ez NG, Pinyol R et al (2021) NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592(7854):450\u2013456","journal-title":"Nature"},{"issue":"1","key":"2645_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1053\/j.gastro.2020.09.031","volume":"160","author":"B Heinrich","year":"2021","unstructured":"Heinrich B, Brown ZJ, Diggs LP et al (2021) Steatohepatitis impairs T-cell\u2013directed immunotherapies against liver tumors in mice. Gastroenterology 160(1):331-345.e6","journal-title":"Gastroenterology"},{"issue":"2","key":"2645_CR19","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1016\/j.jhep.2023.04.012","volume":"79","author":"T Meyer","year":"2023","unstructured":"Meyer T, Galani S, Lopes A, Vogel A (2023) Aetiology of liver disease and response to immune checkpoint inhibitors: an updated meta-analysis confirms benefit in those with non-viral liver disease. J Hepatol 79(2):e73\u2013e76","journal-title":"J Hepatol"},{"issue":"5","key":"2645_CR20","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1159\/000537915","volume":"13","author":"F Rossari","year":"2024","unstructured":"Rossari F, Tada T, Suda G et al (2024) Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study. Liver Cancer 13(5):522\u2013536","journal-title":"Liver Cancer"},{"issue":"2","key":"2645_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"12","key":"2645_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15(12):550","journal-title":"Genome Biol"},{"key":"2645_CR23","doi-asserted-by":"crossref","unstructured":"Chow AKM, Ng L, Lam CSC, Takehara T, ed et al (2013) The enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS ONE 8(11):e78675","DOI":"10.1371\/journal.pone.0078675"},{"issue":"6","key":"2645_CR24","doi-asserted-by":"publisher","first-page":"7207","DOI":"10.18632\/oncotarget.6889","volume":"7","author":"T Tomonari","year":"2016","unstructured":"Tomonari T, Takeishi S, Taniguchi T et al (2016) MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma. Oncotarget 7(6):7207\u20137215","journal-title":"Oncotarget"},{"issue":"4","key":"2645_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14040910","volume":"14","author":"G Fouquet","year":"2022","unstructured":"Fouquet G, Mari\u00e9 C, Collet L et al (2022) Rescuing SLAMF3 expression restores sorafenib response in hepatocellular carcinoma cells through the induction of mesenchymal-to-epithelial transition. Cancers 14(4):910","journal-title":"Cancers"},{"issue":"6","key":"2645_CR26","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.7150\/ijms.51256","volume":"18","author":"Y Ma","year":"2021","unstructured":"Ma Y, Xu R, Liu X et al (2021) LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells. Int J Med Sci 18(6):1456\u20131464","journal-title":"Int J Med Sci"},{"issue":"12","key":"2645_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123026","volume":"13","author":"H Moon","year":"2021","unstructured":"Moon H, Ro SW (2021) MAPK\/ERK signaling pathway in hepatocellular carcinoma. Cancers 13(12):3026","journal-title":"Cancers"},{"issue":"10","key":"2645_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202003404","volume":"8","author":"H Zhang","year":"2021","unstructured":"Zhang H, Xia Y, Wang F et al (2021) Aldehyde dehydrogenase 2 mediates alcohol\u2010induced colorectal cancer immune escape through stabilizing PD\u2010L1 expression. Adv Sci 8(10):2003404","journal-title":"Adv Sci"},{"issue":"9","key":"2645_CR29","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/ijc.24868","volume":"126","author":"Z Zhu","year":"2010","unstructured":"Zhu Z, Hao X, Yan M et al (2010) Cancer stem\/progenitor cells are highly enriched in CD133+ CD44+ population in hepatocellular carcinoma. Int J Cancer 126(9):2067\u20132078","journal-title":"Int J Cancer"},{"issue":"4","key":"2645_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03596-w","volume":"12","author":"X Luo","year":"2021","unstructured":"Luo X, Zheng E, Wei L et al (2021) The fatty acid receptor CD36 promotes HCC progression through activating Src\/PI3K\/AKT axis-dependent aerobic glycolysis. Cell Death Dis 12(4):328","journal-title":"Cell Death Dis"},{"issue":"12","key":"2645_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells12121605","volume":"12","author":"WW Feng","year":"2023","unstructured":"Feng WW, Zuppe HT, Kurokawa M (2023) The role of CD36 in cancer progression and its value as a therapeutic target. Cells 12(12):1605","journal-title":"Cells"},{"issue":"3","key":"2645_CR32","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1007\/BF00197271","volume":"88","author":"HW Goedde","year":"1992","unstructured":"Goedde HW, Agarwal DP, Fritze G et al (1992) Distribution of ADH2 and ALDH2 genotypes in different populations. Hum Genet 88(3):344\u2013346","journal-title":"Hum Genet"},{"issue":"5","key":"2645_CR33","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jhep.2019.06.018","volume":"71","author":"W Seo","year":"2019","unstructured":"Seo W, Gao Y, He Y et al (2019) ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles. J Hepatol 71(5):1000\u20131011","journal-title":"J Hepatol"},{"issue":"1","key":"2645_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/alcalc\/agad077","volume":"59","author":"T Lehner","year":"2024","unstructured":"Lehner T, Gao B, Mackowiak B (2024) Alcohol metabolism in alcohol use disorder: a potential therapeutic target. Alcohol Alcohol 59(1):agad077","journal-title":"Alcohol Alcohol"},{"issue":"3","key":"2645_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.slasd.2024.100154","volume":"29","author":"IC Ferreira","year":"2024","unstructured":"Ferreira IC, Torrej\u00f3n E, Abecasis B et al (2024) Aldehyde dehydrogenase 2 (ALDH2): a novel sorafenib target in hepatocellular carcinoma unraveled by the proteome-wide cellular thermal shift assay. SLAS Discov 29(3):100154","journal-title":"SLAS Discov"},{"issue":"4","key":"2645_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1159\/000513486","volume":"10","author":"S Qin","year":"2021","unstructured":"Qin S, Ren Z, Feng YH et al (2021) Atezolizumab plus bevacizumab versus sorafenib in the Chinese subpopulation with unresectable hepatocellular carcinoma: phase 3 randomized, open-label IMbrave150 study. Liver Cancer 10(4):296\u2013308","journal-title":"Liver Cancer"},{"issue":"1","key":"2645_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A et al (2021) Hepatocellular carcinoma. Nat Rev Dis Primers 7(1):6","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"2645_CR38","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.1016\/S2468-2667(24)00107-5","volume":"9","author":"M Schwarzinger","year":"2024","unstructured":"Schwarzinger M, Ferreira-Borges C, Neufeld M, Alla F, Rehm J (2024) Alcohol rehabilitation and cancer risk: a nationwide hospital cohort study in France. Lancet Public Health 9(7):e461\u2013e469","journal-title":"Lancet Public Health"},{"issue":"10152","key":"2645_CR39","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","volume":"392","author":"MG Griswold","year":"2018","unstructured":"Griswold MG, Fullman N, Hawley C et al (2018) Alcohol use and burden for 195 countries and territories, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 392(10152):1015\u20131035","journal-title":"Lancet"},{"issue":"11","key":"2645_CR40","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.bulcan.2018.07.006","volume":"105","author":"C Hamant","year":"2018","unstructured":"Hamant C, Deneuve S, Albaret MA et al (2018) Accompagnement des d\u00e9pendances \u00e0 l\u2019alcool et au tabac des patients atteints d\u2019un cancer des voies a\u00e9rodigestives sup\u00e9rieures. Bull Cancer 105(11):1012\u20131019","journal-title":"Bull Cancer"}],"container-title":["Journal of Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02645-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00109-026-02645-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00109-026-02645-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T03:01:25Z","timestamp":1769310085000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00109-026-02645-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,25]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["2645"],"URL":"https:\/\/doi.org\/10.1007\/s00109-026-02645-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6837338\/v1","asserted-by":"object"}]},"ISSN":["0946-2716","1432-1440"],"issn-type":[{"value":"0946-2716","type":"print"},{"value":"1432-1440","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,25]]},"assertion":[{"value":"11 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patients are part of the CHIEF cohort (French National Cohort of HCC patients, NCT04348838). All included patients provided signed and informed consent for the anonymous use of their clinical and biological data. The study was approved by local ethics committees: \u201cComit\u00e9 de Protection des Personnes Sud-Est IV\u201d (Agence R\u00e9gionale de sant\u00e9 d\u2019Auvergne-Rh\u00f4ne-Alpes). The study is classified as MR01 issued by la Commission Nationale de l\u2019Informatique et des Libert\u00e9s (CNIL).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The clinical trial number of the CHIEF cohort is NCT04348838, registered under registration number 19.04.15.41412 by the \u201cComit\u00e9 de Protection des Personnes Sud-Est IV\u201d (RCB ID: 2019-A00679-48).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"34"}}